Table 2 Rate of pseudoprogression in patients with melanoma or NSCLC
First author, year [reference] | Number of patients | Type of cancer | Treatment | Pseudoprogression (%) |
|---|---|---|---|---|
Wolchock, 2009 [17] | 227 | Melanoma | Ipilimumab | 9.7 |
Hodi, 2016 [26] | 327 | Melanoma | Pembrolizumab | 7.0 |
Nishino, 2017 [24] | 107 | Melanoma | Pembrolizumab | 5.0 |
Gettinger, 2015 [84] | 129 | NSCLC | Nivolumab | 5.0 |
Nishino, 2017 [85] | 160 | NSCLC | Nivolumab or pembrolizumab | 0.6 |
Katz, 2018 [86] | 166 | NSCLC | Anti-PD1 (nivolumab 80%) | 2.0 |
Fujimoto, 2019 [27] | 542 | NSCLC | Nivolumab | 3.0 |